Published in J Clin Endocrinol Metab on April 08, 2008
Adiponectin and cardiovascular health: an update. Br J Pharmacol (2012) 1.42
Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham Offspring Study. Obesity (Silver Spring) (2011) 1.05
Association of adiponectin with left ventricular mass in blacks: the Jackson Heart Study. Circ Heart Fail (2011) 1.04
Relations of plasma total and high-molecular-weight adiponectin to new-onset heart failure in adults ≥65 years of age (from the Cardiovascular Health study). Am J Cardiol (2013) 0.99
Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol (2011) 0.95
Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev (2013) 0.92
Bariatric surgery to unload the stressed heart: a metabolic hypothesis. Am J Physiol Heart Circ Physiol (2012) 0.90
Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev (2010) 0.86
Adiponectin provides cardiovascular protection in metabolic syndrome. Cardiol Res Pract (2011) 0.80
Obesity and preclinical changes of cardiac geometry and function. Korean Circ J (2010) 0.79
Angiotensin II reduces cardiac AdipoR1 expression through AT1 receptor/ROS/ERK1/2/c-Myc pathway. PLoS One (2013) 0.79
Adipokines and the Right Ventricle: The MESA-RV Study. PLoS One (2015) 0.76
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2005) 11.91
Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology (2003) 3.59
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int (2008) 3.27
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest (2014) 3.10
alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One (2010) 2.94
Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81
Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol (2005) 2.75
Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. Diabetes (2007) 2.73
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care (2005) 2.53
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology (2007) 2.50
Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes (2010) 2.44
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology (2009) 2.39
Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension (2004) 2.33
Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes (2011) 2.21
Thyroid disorders in chronic hepatitis C. Am J Med (2004) 2.19
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes (2002) 2.06
Physical activity and insulin sensitivity: the RISC study. Diabetes (2008) 2.03
Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab (2006) 1.98
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes (2007) 1.96
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol (2007) 1.92
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care (2005) 1.83
Whey and casein labeled with L-[1-13C]leucine and muscle protein synthesis: effect of resistance exercise and protein ingestion. Am J Physiol Endocrinol Metab (2010) 1.82
Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens (2009) 1.76
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev (2004) 1.74
Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab (2002) 1.73
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology (2009) 1.71
Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes (2005) 1.71
Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab (2002) 1.71
Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes (2002) 1.69
Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care (2003) 1.68
Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology (2006) 1.66
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab (2011) 1.63
Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab (2003) 1.61
Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens (2009) 1.61
Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet (2009) 1.61
Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab (2006) 1.61
Adiponectin and lipoprotein particle size. Diabetes Care (2009) 1.60
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care (2007) 1.57
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Effects of age and physical fitness on microcirculatory function. Clin Sci (Lond) (2004) 1.55
Contrasting effects of acute and chronic cigarette smoking on skin microcirculation in young healthy subjects. J Hypertens (2004) 1.53
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 1.53
The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care (2006) 1.52
Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes (2002) 1.51
Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J Hypertens (2003) 1.49
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab (2007) 1.49
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart (2012) 1.47
Epicardial coronary artery size in hypertensive and physiologic left ventricular hypertrophy. Am J Hypertens (2007) 1.46
Human growth hormone responses to repeated bouts of sprint exercise with different recovery periods between bouts. J Appl Physiol (1985) (2005) 1.45
Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology (2012) 1.44
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab (2006) 1.44
Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens (2010) 1.43
Relationship between carotid artery mechanics and the spontaneous baroreflex: a noninvasive investigation in normal humans. J Hypertens (2012) 1.42
Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes (2013) 1.41
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab (2006) 1.41
Impaired endothelium independent vasodilation in nonobstructive hypertrophic cardiomyopathy. Am J Hypertens (2011) 1.40
[Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) (2008) 1.39
Pain-inducing imagery as a function of hypnotisability and of the activity of Gray's Behavioral Inhibition/Activation Systems. Neurosci Lett (2013) 1.38
Mesenchymal stem cell ingrowth and differentiation on coralline hydroxyapatite scaffolds. Biomaterials (2006) 1.38
Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. J Physiol (2009) 1.36
Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care (2005) 1.35
Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol (2006) 1.34
Assessment of early diabetic renal changes with hyperpolarized [1-(13) C]pyruvate. Diabetes Metab Res Rev (2013) 1.34
Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care (2007) 1.32
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care (2011) 1.31
Cardiovascular disease and insulin-like growth factor I. Circulation (2002) 1.30
A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab (2003) 1.30
Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol (2006) 1.29
Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. J Clin Endocrinol Metab (2006) 1.29